Jason Pitts, PhD

Jason joined Sofinnova as an Associate in 2018. In 2019, he was promoted to Principal. He focuses on therapeutics investments. Jason led the investment in Karuna and serves as a board observer for Velos Biopharma and Cincor Pharma.

Prior to joining Sofinnova, Jason was a consultant with McKinsey & Company, focusing primarily on operational and strategic R&D issues for top companies in pharmaceuticals and medical products. Before transitioning to consulting, Jason studied the genetic mechanisms of neurodegenerative disease as a graduate student at The Rockefeller University in the lab of Dr. Marc Tessier-Lavigne, founder of Denali Therapeutics and current Stanford University president. Prior to enrolling at Rockefeller, Jason worked as a research associate at Regeneron Pharmaceuticals, Inc.

Jason received his PhD in Neuroscience from The Rockefeller University, where he was awarded The David Rockefeller Fellowship. Jason also holds a BS in Neurobiology and Behavior from Cornell University.
Speaking In
3:00 PM - 3:55 PM
Tuesday, February 11
In recent months, the exits of several large companies from the neuroscience space, optimistic…
Lyceum Complex